SCHEMBL20549895

SCHEMBL20549895

C[C@H](N)[C@@H]1CCN(c2ccc3cc(C(=O)O)c(=O)n4c3c2OC[C@@H]4C)C1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 8/20 0.72
IRAK4 Q9NWZ3 1/20 0.35
SCN5A Q14524 2/20 0.34
AADAT Q8N5Z0 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
CACNA1C Q13936 1/20 0.34
KDM4E B2RXH2 4/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
ALB P02768 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
TUBB4A P04350 1/20 0.32
POLB P06746 1/20 0.32
TUBB P07437 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20549897 1.00 KCNH2 (0.72) KCNH2IRAK4SCN5AAADATCYP1A2
SCHEMBL20549479 0.85 KCNH2 (0.58) KCNH2SCN5AAADATCYP1A2CYP3A4
SCHEMBL20549480 0.85 KCNH2 (0.58) KCNH2SCN5AAADATCYP1A2CYP3A4
SCHEMBL20549836 0.85 KCNH2 (0.53) KCNH2SCN5AAADATCYP1A2CYP3A4
SCHEMBL20549840 0.85 KCNH2 (0.53) KCNH2SCN5AAADATCYP1A2CYP3A4
SCHEMBL20549484 0.84 KCNH2 (1.00) KCNH2SCN5AAADATCYP3A4KDM4E
SCHEMBL20549571 0.80 KCNH2 (0.50) KCNH2SCN5AAADATCYP1A2CYP3A4
SCHEMBL20549572 0.80 KCNH2 (0.50) KCNH2SCN5AAADATCYP1A2CYP3A4
SCHEMBL20549526 0.78 KCNH2 (0.75) KCNH2SCN5AAADATKDM4EKMT2A
SCHEMBL20549317 0.75 KCNH2 (0.57) KCNH2AADATKDM4EKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318311-A1 TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2018-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180318311-A1 TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS TOP1, TOP2A, TOP2B KCNH2 2920/4885IRAK4 3828/4885SCN5A 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.